Precision peptide theranostics: developing N - to C -terminus optimized theranostics targeting cholecystokinin-2 receptor
Theranostics · 2024
DOI: 10.7150/thno.89701 ↗Kurz gefasst
Fachartikel in der Zeitschrift Theranostics, 2024. Verfasst von Marwa N Rahimi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiopharmaceutical Sciences, Cancer Imaging, The Peter MacCallum Cancer Centre, Victoria 3000, Australia. Hauptthemen laut MEDLINE: Receptor, Cholecystokinin B, Gallium Radioisotopes. Die Arbeit wurde bisher 8-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Peptides are ideal for theranostic development as they afford rapid target accumulation, fast clearance from background tissue, and exhibit good tissue penetration. Previously, we developed a novel series of peptides that presented discreet folding propensity leading to an optimal candidate [68Ga]Ga-DOTA-GA1 ([D-Glu]6-Ala-Tyr-NMeGly-Trp-NMeNle-Asp-Nal-NH2) with 50 pM binding affinity against cholecystokinin-2 receptors (CCK2R). However, we were confronted with challenges of unfavorably high renal uptake.
Methods
A structure activity relationship study was undertaken of the lead theranostic candidate. Prudent structural modifications were made to the peptide scaffold to evaluate the contributions of specific N-terminal residues to the overall biological activity. Optimal candidates were then evaluated in nude mice bearing transfected A431-CCK2 tumors, and their biodistribution was quantitated ex vivo.
Results
We identified and confirmed that D-Glu3 to D-Ala3 substitution produced 2 optimal candidates, [68Ga]Ga-DOTA-GA12 and [68Ga]Ga-DOTA-GA13. These radiopeptides presented with high target/background ratios, enhanced tumor retention, excellent metabolic stability in plasma and mice organ homogenates, and a 4-fold reduction in renal uptake, significantly outperforming their non-alanine counterparts.
Conclusions
Our study identified novel radiopharmaceutical candidates that target the CCK2R. Their high tumor uptake and reduced renal accumulation warrant clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiopharmaceutical Sciences, Cancer Imaging, The Peter MacCallum Cancer Centre, Victoria 3000, Australia.
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria 3010, Australia.
- Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia.
- Models of Cancer Translational Research Centre, The Peter MacCallum Cancer Centre, Victoria 3000, Australia.
- The Bio21 Institute, School of Chemistry, The University of Melbourne, Melbourne, Victoria, 3010 Australia.
- Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University (Parkville Campus), Parkville, Victoria 3052, Australia.
Zitieren
APA
Rahimi, M. N., Corlett, A., Van Zuylekom, J., Sani, M. A., Blyth, B., Thompson, P., Roselt, P. D., & Haskali, M. B. (2024). Precision peptide theranostics: developing N - to C -terminus optimized theranostics targeting cholecystokinin-2 receptor. Theranostics. https://doi.org/10.7150/thno.89701
Vancouver
Rahimi MN, Corlett A, Van Zuylekom J, Sani MA, Blyth B, Thompson P, et al. Precision peptide theranostics: developing N - to C -terminus optimized theranostics targeting cholecystokinin-2 receptor. Theranostics. 2024. doi:10.7150/thno.89701
BibTeX
@article{Rahimi2024,
author = {Rahimi, Marwa N and Corlett, Alicia and Van Zuylekom, Jessica and Sani, Marc Antoine and Blyth, Benjamin and Thompson, Philip and Roselt, Peter D and Haskali, Mohammad B},
title = {Precision peptide theranostics: developing N - to C -terminus optimized theranostics targeting cholecystokinin-2 receptor},
journal = {Theranostics},
year = {2024},
doi = {10.7150/thno.89701}
}
EUVIMED